Teva, a pharmaceutical company, indicated in a securities filing that an internal probe revealed business practices to likely have violated the Foreign Corrupt Practices Act.
The drug indicated before it was looking into matters in multiple countries that may lead to a rise of FCPA violations and/or possible violations to local laws, based on a securities filing last year.
Teva said its internal investigation started after receiving subpoenas and further requests on details related to foreign bribery from the SEC (Securities and Exchange Commission) and the Justice Department beginning in 2012.
The probe revealed business practices and transactions in Eastern Europe, Latin America, and Russia which is said to likely violate FCPA and local laws.
Teva previously mentioned that it may end up paying fines in relation to the FCPA investigation. The drug maker also mentioned that its affiliates in specific countries who are being investigated offered local authorities false or altered details on their marketing processes.